Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » New Biomarkers for Glioma Treatment Response
Clinical Breakthroughs

New Biomarkers for Glioma Treatment Response

By Will DossSep 15, 2020
Share
Facebook Twitter Email
Stewart Goldman, MD, chief of Hematology, Oncology, and Stem Cell Transplantation in the Department of Pediatrics, was a co-author of the study published in the Journal of Clinical Investigation.

Biomarkers using mass cytometry can assess patient response to an emerging vaccine for a specific pediatric brain tumor, according to a recent multi-center study published in the Journal of Clinical Investigation.

These findings show the vaccine is safe and the biomarkers could improve clinical trials for the peptide vaccine, according to Stewart Goldman, MD, chief of Hematology, Oncology, and Stem Cell Transplantation in the Department of Pediatrics and a co-author of the study.

“These findings will allow future trials to better understand whom to offer these therapies to, and what medications we need to avoid as to not decrease efficacy,” said Goldman, who is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “

Diffuse midline gliomas (DMG) and diffuse intrinsic pontine gliomas (DIPG) are deadly pediatric brain cancers: less than 10 percent of patients survive beyond two years. Traditionally these tumors are treated with radiation therapy, but immunotherapy treatments have gained attention in recent years, according to the study.

Previously, the study authors created a peptide vaccine for diffuse gliomas. This vaccine uses a mutation common in diffuse gliomas to trigger an immune response targeted at cancer cells — in essence, pointing the immune system at cells with this mutation and letting them attack the cancerous cells. In the current study, investigators tested safety and monitoring of the vaccine, enrolling 29 patients.

The vaccine was well-tolerated with no serious adverse events, according to the study. In addition, immunological responses were measured using mass cytometry on blood cells.

Mass cytometry allowed the investigators to measure how many T-cells were reactive to the cancer, as intended by the peptide vaccine. Increasing levels of reactive T-cells were associated with a better prognosis for patients, according to the study.

Other cytometry measures included measuring myeloid cells to predict patient response to the treatment — demonstrating that mass cytometry on blood samples is a viable surveillance method, according to Goldman.

“We showed that immunologic monitoring of patients receiving the vaccine therapy can reveal predictive biomarkers for response and efficacy,” Goldman said.

Now that the vaccine has passed its first test, Goldman said he hopes it can move through the trial process and that other diffuse glioma treatments can take advantage of the monitoring framework laid out here.

“This study clearly warrants further investigation and I hope using cytometry and other methodologies to monitor response will guide physicians in their therapeutic choices in the future,” Goldman said.

This study was supported by the V Foundation, the Pacific Pediatric Neuro-Oncology Consortium Foundation, the Pediatric Brain Tumor Foundation, Mithil Prasad Foundation, the MCJ Amelior Foundation, the Anne and Jason Farber Foundation, Will Power Research Fund Inc., the Isabella Kerr Molina Foundation, the Parker Institute for Cancer Immunotherapy and the National Institutes of Health National Institute of Neurological Disorders and Stroke grant R35 NS105068.

Cancer Pediatrics Research
Share. Facebook Twitter Email

Related Posts

Largest cell map of human lung reveals insights into disease

Jun 8, 2023

Biological Aging Increases Risk of Depression, Anxiety in Adults 

Jun 7, 2023

Developing New Nanoparticle Treatments for Brain Tumors

Jun 6, 2023

Comments are closed.

Latest News

Largest cell map of human lung reveals insights into disease

Jun 8, 2023

McNally Honored with Walder Award

Jun 8, 2023

Biological Aging Increases Risk of Depression, Anxiety in Adults 

Jun 7, 2023

Developing New Nanoparticle Treatments for Brain Tumors

Jun 6, 2023

Newly Discovered Mechanisms Increase Chemotherapy Resistance in Breast Cancer 

Jun 5, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
ANB05555
ANB08990
ANB09022
ANB09063
ANB09008
ANB08781
ANB08971
ANB09000
ANB08992
ANB09015
ANB09058
ANB09048

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.